Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.54 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.52 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.52 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29648185 | 1.00 | DGAT1 (0.56) | DGAT1MEN1KMT2ARAB9AMAP2K3 | |
| SCHEMBL9792961 | 0.86 | PIM1 (0.50) | DGAT1IRAK4KDM4ETSHRSCN9A | |
| SCHEMBL3126744 | 0.85 | SCN9A (0.59) | SCN9A | |
| SCHEMBL16129942 | 0.85 | ALDH1A1 (0.62) | DGAT1IRAK4ALDH1A1HSD17B10HPGD | |
| SCHEMBL28052676 | 0.85 | SCN9A (0.57) | DGAT1MAP2K3IRAK4CASP1SCN9A | |
| SCHEMBL16129931 | 0.85 | SCN9A (0.56) | DGAT1MAP2K3PARP1IRAK4SCN9A | |
| SCHEMBL29911672 | 0.85 | SCN9A (0.57) | DGAT1MAP2K3IRAK4CASP1SCN9A | |
| SCHEMBL208097 | 0.84 | KDM4E (0.64) | MEN1KMT2ARAB9AASIC3KAT6A | |
| SCHEMBL5109866 | 0.84 | HSD17B14 (0.60) | MEN1KMT2ARAB9AMAP2K3PARP1 | |
| SCHEMBL28876906 | 0.84 | SCN9A (0.62) | DGAT1HSD17B14SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660507-B2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | MILLENNIUM PHARM INC (US) | 2017-01-04 | — | — | EP | claimed |
| US-8283367-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2012-10-09 | — | — | US | claimed |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2011-06-16 | — | — | US | claimed |
| US-7915236-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-03-29 | — | — | US | claimed |
| EP-1660507-B9 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-03-24 | — | — | EP | claimed |
| EP-1846424-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-01-27 | — | — | EP | claimed |
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2009-11-26 | — | — | US | claimed |
| EP-1660507-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2009-08-05 | — | — | EP | claimed |
| US-7468383-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2008-12-23 | — | — | US | claimed |
| EP-1846424-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2007-10-24 | — | — | EP | claimed |
| CN-1867572-A | proteasome inhibitors and methods of use thereof | CEPHALON INC (US) | 2006-11-22 | — | — | CN | claimed |
| US-20060189806-A1 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2006-08-24 | — | — | US | claimed |
| WO-2006086600-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2006-08-17 | — | — | WO | claimed |
| EP-1660507-A2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2006-05-31 | — | — | EP | claimed |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | claimed |
| WO-2005021558-A2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2005-03-10 | — | — | WO | claimed |
| EP-3666274-A1 | CARBOXAMIDE DERIVATIVES AND USE THEREOF | Purdue Pharma LP (US) | 2020-06-17 | — | — | EP | disclosed |
| EP-1660507-B2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | MILLENNIUM PHARM INC (US) | 2017-01-04 | — | — | EP | disclosed |
| US-20060189806-A1 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | PSMB11, PSMB5, PSMB6 | DGAT1 4058/4885MEN1 2324/4885KMT2A 2266/4885 |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | DGAT1 4058/4885MEN1 2324/4885KMT2A 2266/4885 |
| US-20060189806-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | DGAT1 4034/4885MEN1 2309/4885KMT2A 2205/4885 |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | PSMB11, PSMB5, PSMB6 | DGAT1 4058/4885MEN1 2324/4885KMT2A 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.